Patent · US Active

Substituted [1,2,4]triazolo[4,3-a]pyrazines as BRD4 inhibitors

US10328074B2 · kind B2 · utility

26Cited by

7References

25Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Harald Engelhardt · Ebreichsdorf, AT
Davide Gianni · Wien, AT
Christian Alan Paul Smethurst · Wien, AT

Key dates

Filing date	Jan 14, 2016
Grant date	Jun 25, 2019
Priority date	—
Expiry date	Jan 14, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Method for treating AML and MM by administration of a compound of the formula (I) wherein the groups R1 to R3 have the meanings given in the specification.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.